Cargando…

Enhancing the Immunogenicity of RBD Protein Variants through Amino Acid E484 Mutation in SARS-CoV-2

In the context of the COVID-19 pandemic, conducting antibody testing and vaccination is critical. In particular, the continued evolution of SARS-CoV-2 raises concerns about the effectiveness of vaccines currently in use and the activity of neutralizing antibodies. Here, we used the Escherichia coli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhikai, Wan, Xuan, Li, Xinyue, Cai, Shaoxi, Wan, Chengsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506138/ https://www.ncbi.nlm.nih.gov/pubmed/36146826 http://dx.doi.org/10.3390/v14092020

Ejemplares similares

Effects of a Shift of the Signal Peptide Cleavage Site in Signal Peptide Variant on the Synthesis and Secretion of SARS-CoV-2 Spike Protein
por: Zhang, Zhikai, et al.
Publicado: (2022)

Rapid and accurate identification of SARS-CoV-2 variants containing E484 mutation
por: Zhang, Yuan, et al.
Publicado: (2021)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron
por: Schröder, Simon, et al.
Publicado: (2023)

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Identification of E484K and other novel SARS-COV-2 variants from the Kingdom of Bahrain
por: Bindayna, Khalid Mubarak, et al.
Publicado: (2021)

E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil
por: Ferrareze, Patrícia Aline Gröhs, et al.
Publicado: (2021)

SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations
por: Yang, Wan-Ting, et al.
Publicado: (2022)

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies
por: Wang, Wei Bu, et al.
Publicado: (2021)

RPA-ligation-qPCR combined method for genotyping the SARS-CoV-2 key mutation E484Q: Genotyping SARS-CoV-2 E484Q by RPA-ligation-qPCR
por: Wang, Pei, et al.
Publicado: (2022)

Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy
por: Baj, Andreina, et al.
Publicado: (2021)

A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations
por: Zhao, Yanan, et al.
Publicado: (2021)

De novo emergence of the mutation E484K in a SARS-CoV-2 B.1.1.7 lineage variant()
por: Urrutikoetxea-Gutierrez, Mikel, et al.
Publicado: (2022)

Author Correction: Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil
por: Nonaka, Carolina K. V., et al.
Publicado: (2021)

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
por: Jensen, Bjoern, et al.
Publicado: (2021)

An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice
por: Govea-Alonso, Dania O., et al.
Publicado: (2022)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Yang, Lin, et al.
Publicado: (2021)

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2
por: Peiffer-Smadja, Nathan, et al.
Publicado: (2021)

CRISPR-Cas12a-Based Detection of SARS-CoV-2 Harboring the E484K Mutation
por: Marqués, María-Carmen, et al.
Publicado: (2021)

Genomic Sequencing of SARS-CoV-2 E484K Variant B.1.243.1, Arizona, USA
por: Skidmore, Peter T., et al.
Publicado: (2021)

Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD—A Target for Vaccine Development
por: Gupta, Deepali, et al.
Publicado: (2022)

Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK
por: Toovey, Oliver T.R., et al.
Publicado: (2021)

Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern
por: Pondé, R.A.A.
Publicado: (2022)

SARS-COV-2 RBD (Receptor binding domain) mutations and variants (A sectional-analytical study)
por: Hajizadeh, Faezeh, et al.
Publicado: (2022)

Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants
por: da Costa, Clauber Henrique Souza, et al.
Publicado: (2022)

α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants
por: Zou, Jintao, et al.
Publicado: (2021)

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion
por: Ferreira, Isabella A T M, et al.
Publicado: (2021)

Luciferase Immunosorbent Assay Based on Multiple E Antigens for the Detection of Chikungunya Virus-Specific IgG Antibodies
por: Li, Xiaoxia, et al.
Publicado: (2022)

Emergence of SARS-CoV-2 Variant B.1.575.2, Containing the E484K Mutation in the Spike Protein, in Pamplona, Spain, May to June 2021
por: Trobajo-Sanmartín, Camino, et al.
Publicado: (2021)

Immunogenicity and safety of a RBD vaccine against SARS-CoV-2 in a murine model
por: Díaz, Andrés, et al.
Publicado: (2022)

Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein
por: Dormeshkin, Dmitri, et al.
Publicado: (2023)

435. Outcomes for E484K Mutation Negative COVID-19 Patients Cohorted with E484K Mutation Positive COVID-19 Patients: A Retrospective Cohort Study
por: Buskandar, Fahad, et al.
Publicado: (2021)

Erratum for Li et al., “Luciferase Immunosorbent Assay Based on Multiple E Antigens for the Detection of Chikungunya Virus-Specific IgG Antibodies”
por: Li, Xiaoxia, et al.
Publicado: (2022)

Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells
por: Gerez, Guillaume, et al.
Publicado: (2022)

Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD
por: Li, Qianqian, et al.
Publicado: (2022)

Comparative immunogenicity analysis of intradermal versus intramuscular administration of SARS-CoV-2 RBD epitope peptide-based immunogen In vivo
por: Yadav, Naveen, et al.
Publicado: (2021)

COVID-19: S-Peptide RBD (484–508) Induces IFN-γ T-Cell Response in Naïve-to-Infection and Unvaccinated Subjects with Close Contact with SARS-CoV-2-Positive Patients
por: Murdocca, Michela, et al.
Publicado: (2023)

Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
por: Pasquevich, Karina A., et al.
Publicado: (2023)

Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan
por: Hirotsu, Yosuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_34cj769oe8ppmmn2lbc6p305c0